Perinatal Depression Treatment in a Pediatric Setting- Pilot Phase

Overview

The purpose of this project is to test whether a new model of collaborative care depression treatment adapted to the needs and preferences of low-income, urban mothers with perinatal depression and to a pediatric clinic setting increases engagement in and adherence to perinatal depression treatment.

Full Title of Study: “Adapting Collaborative Care Perinatal Depression Treatment to a Pediatric Setting – Pilot Phase”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2012

Detailed Description

This research project consists of two phases that are designed, in sequence, to adapt standard collaborative care depression treatment to the unique needs of low-income depressed postpartum women and to the pediatric setting where women will receive the treatment. These adaptations, in turn, are designed to improve maternal engagement in and adherence to depression treatment, the primary outcomes at this early stage of intervention development. Phase I is the initial pilot project in which the model will be developed. We will 1) adapt standard collaborative care depression models into the Mother-Infant Treatment Team (MITT) intervention and develop a procedure manual based on maternal and provider input, 2) pilot the MITT intervention with 10 depressed mothers to test the feasibility of implementing the model, and 3) evaluate the experiences of participating mothers and providers to revise and finalize MITT processes and procedures. Phase II will be an open label trial of MITT to determine whether MITT is associated with improved maternal engagement and adherence to depression treatment. We will pilot MITT with 10 mothers to determine the feasibility of implementing MITT. We will collect recruitment and logistical feasibility measures. We will also determine engagement and adherence rates to treatment as well as the effort required to engage women in treatment. We will determine mothers' and providers' perceptions of their experiences with MITT and will use all of this information to revise the MITT protocol in preparation for Phase II.

Interventions

  • Other: Mother-Infant Treatment Team
    • This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.

Arms, Groups and Cohorts

  • Experimental: MITT
    • Mothers will be assigned to the Mother-Infant Treatment Team (MITT)and will receive either psychotherapy or sertraline or both as well as outreach.

Clinical Trial Outcome Measures

Primary Measures

  • Treatment Engagement
    • Time Frame: 6 weeks
  • Treatment Adherence
    • Time Frame: 18 weeks

Secondary Measures

  • Treatment Response
    • Time Frame: 12 weeks
  • Treatment Remission
    • Time Frame: 12 weeks
  • Maternal functional assessment
    • Time Frame: 12 weeks
  • Maternal healthcare utilization
    • Time Frame: 18 weeks
  • Infant healthcare utilization
    • Time Frame: 18 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Mothers of infants 12 months of age or younger who present to the Pediatric Practice at Golisano Children's Hospital 2. Women who are 18 years of age or older 3. Mothers who understand and speak English sufficiently to participate in therapy with an English speaking provider 4. Have a current score of > 10 on the EPDS 5. Provide written informed consent 6. Meet criteria for unipolar major depressive disorder. Exclusion Criteria:

Women who: 1. do not speak or understand English well enough to participate in the therapy with an English speaking provider 2. are under 18 years of age 3. children are not cared for at the Pediatric Practice at the Golisano Children's Hospital 4. are actively psychotic, suicidal or homicidal, 5. require treatment (including additional psychotropic medications) not provided by MITT, 6. in the judgment of the MITT psychiatric provider require a higher level of psychiatric care (i.e. partial hospitalization, hospitalization, intensive case management), 7. are in active counseling or psychotherapy, 8. are under the care of a psychiatric provider and/or are receiving active treatment for depression including light therapy, ECT, or antidepressants 9. are receiving psychotropic medications not allowed in this study, 10. previously participated in and/or were terminated from the study, 11. have a diagnosis of bipolar disorder, schizophrenia, other psychotic disorder or alcohol/substance use disorder, and/or 12. have a medical condition or are taking medications that are contraindicated for sertraline

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Rochester
  • Collaborator
    • National Institute of Mental Health (NIMH)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Linda Chaudron, Associate Professor, Department of Psychiatry – University of Rochester
  • Overall Official(s)
    • Linda H Chaudron, MD, MS, Principal Investigator, University of Rochester

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.